L-Ornithine Derived Polyamines in Cystic Fibrosis Airways

Hartmut Grasemann, Darakhshanda Shehnaz, Masahiro Enomoto, Michael Leadley, Jaques Belik, Felix Ratjen

1 Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada, 2 Program in Physiology and Experimental Medicine, SickKids Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Canada

Abstract

Increased arginase activity contributes to airway nitric oxide (NO) deficiency in cystic fibrosis (CF). Whether down-stream products of arginase activity contribute to CF lung disease is currently unknown. The objective of this study was to test whether L-ornithine derived polyamines are present in CF airways and contribute to airway pathophysiology. Polyamine concentrations were measured in sputum of patients with CF and in healthy controls, using liquid chromatography-tandem mass spectrometry. The effect of spermine on airway smooth muscle mechanical properties was assessed in bronchial segments of murine airways, using a wire myograph. Sputum polyamine concentrations in stable CF patients were similar to healthy controls for putrescine and spermidine but significantly higher for spermine. Pulmonary exacerbations were associated with an increase in sputum and spermine levels. Treatment for pulmonary exacerbations resulted in decreases in arginase activity, L-ornithine and spermine concentrations in sputum. The changes in sputum spermine with treatment correlated significantly with changes in L-ornithine but not with sputum inflammatory markers. Incubation of mouse bronchi with spermine resulted in an increase in acetylcholine-induced force and significantly reduced nitric oxide-induced bronchial relaxation. The polyamine spermine is increased in CF airways. Spermine contributes to airways obstruction by reducing the NO-mediated smooth muscle relaxation.

Introduction

The amino acid L-arginine is substrate for enzymatic conversion by nitric oxide synthases (NOSs) and arginases. Recent evidence suggests an imbalance of the L-arginine metabolism in cystic fibrosis (CF) airways towards arginine as the activity of arginase is upregulated and levels of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) are increased in CF sputum. This imbalance contributes to the known decrease in CF airway nitric oxide (NO) production and results in increased concentrations of L-ornithine, the product of arginase activity [1–4] (Figure 1).

While it has been suggested that NO deficiency contributes to pathophysiology of CF lung disease and therapeutic interventions that improve airway NO production also result in improved pulmonary function in CF patients [3], little is known about the potential role of down-stream products of L-ornithine conversion. L-ornithine can be metabolized to proline, the precursor for collagen production by ornithine aminotransferase (OAT) and may as such contribute to pulmonary remodeling and fibrosis [6,7]. L-ornithine is also substrate for ornithine decarboxylase (ODC), which catalyzes its conversion to putrescine, the first step in the polyamine biosynthesis. Putrescine is further metabolized to the higher-order polyamines, spermidine and spermine, by spermidine synthase and spermine synthase, respectively [7,8] (Figure 1).

Polyamines are accumulated in alveolar airway epithelium by active transport, which may suggest that they could play an important functional role in airways [9], but their role in pulmonary diseases is currently unclear. Polyamines could contribute to lung damage, as back-conversion of the higher order polyamines results in formation of toxic compounds such as hydrogen peroxide [9]. Hydrogen peroxide, a product of and contributor to oxidative stress and cellular damage, may also induce contraction of airway smooth muscle [10–12]. On the other hand, polyamines could positively impact on bronchomotor tone, as they have been shown to relax guinea-pig tracheal smooth muscle [13]. Furthermore, polyamines may exhibit anti-inflammatory characteristics as spermine was shown to protect against lethal sepsis when administered systemically in mice [14].

While increased polyamine levels in blood and urine have previously been described in CF patients [15,16] and urinary spermine excretion was positively correlated with CF lung disease severity [15], no information is available on polyamines in the airways of patients with CF. We therefore studied polyamines in CF by assessing polyamine profiles in sputum samples from stable CF patients and during periods of pulmonary exacerbation. In addition, we explored the functional role of the polyamine...
Methods

been previously reported in the form of an abstract [17].

mediated relaxation. Some of the results related to this work have
spermine on airway smooth muscle contraction and nitric oxide

synthase.

S-adenosylmethionine, SpS: spermine synthase, SpdS: spermidine
OAT: ornithine aminotransferase, ODC: L-ornithine decarboxylase, SAM: S-adenosylmethionine, SpS: spermine synthase, SpdS: spermidine synthase.
doi:10.1371/journal.pone.0046618.g001

Figure 1. L-Arginine metabolism in cystic fibrosis sputum.
ADMA: asymmetric dimethylarginine, ARG: arginase, CAT: cationic amino acid transporter, NO: nitric oxide, NOS: nitric oxide synthase, OAT: ornithine aminotransferase, ODC: L-ornithine decarboxylase, SAM: S-adenosylmethionine, SpS: spermine synthase, SpdS: spermidine synthase.
doi:10.1371/journal.pone.0046618.g001

spermine on airway smooth muscle contraction and nitric oxide mediated relaxation. Some of the results related to this work have been previously reported in the form of an abstract [17].

Patients and study design

The study was approved by the Institutional Research Ethics Board; written informed consent was obtained in all cases. The diagnosis of CF had been confirmed by repeated sweat tests (chloride >60 mmol/L) and CFTR gene mutation analysis in all patients. Clinically stable patients were recruited during clinic visits. Sputum from CF patients with a pulmonary exacerbation was obtained within the first two days of hospital admission and after 14 days of intravenous (i.v.) antibiotic treatment. Healthy subjects had to be non-smokers and free of a respiratory tract infection for at least two weeks prior to recruitment.

Sputum from CF patients was collected after either spontaneous expectoration or induction with inhaled hypertonic saline as previously described [18]. Samples from patients with signs of pulmonary hemorrhage were excluded as the concentrations of spermidine and spermine were previously reported to be high [19]. Sputum production in all healthy controls was induced by expectoration or induction with inhaled hypertonic saline as recently described [18]. Briefly, adult C57Bl/6 mice were sacrificed, 3rd–4th generation intralobar bronchial segments from the left lung were mounted in a wire myograph and isometric changes were digitized and recorded (Myodaq, Danish Myo Technology A/S, Aarhus, Denmark). Tissues were bathed in Krebs-Henseleit buffer bubbled with air/6% CO₂ and maintained at 37°C. Bronchial smooth muscle contractile response was normalized to the tissue cross sectional area (mN/mm²). The relaxant response to nitroprusside (SNP) was evaluated following stimulation with the E₁₇ concentration of acetylcholine and expressed as a percentage of the contractile response in the absence and presence of spermine (10⁻⁴ M, 30 min pre-incubation). Procedures were conducted according to criteria established by the Canadian Council on Animal Care and were approved by the institutional Animal Care Review Committee.

Statistical analyses

All results are expressed as the mean ± standard error of the mean (SEM). Binary comparisons were made with two-tailed student’s t-test or Wilcoxon, where appropriate. Paired t-test was used to compare samples from CF patients before and after treatment for a pulmonary exacerbation. Correlations were determined using Spearman’s test. P-values <0.05 were considered significant. Statistical analyses were conducted using GraphPad Prism 4.0c (Graphpad Software Inc., La Jolla, CA USA). The bronchial smooth muscle relaxant responses were evaluated by two-way ANOVA and multiple comparisons obtained by the Tukey-Krammer test.

Results

The demographics of the study subjects are summarized in Table 1. A total of 10 healthy controls and 30 patients with CF (10 stable and 20 patients with a CF pulmonary exacerbation) were included. Sputum microbiology cultures in the stable patients showed no growth in 2 and were positive in 8 patients (Pseudomonas aeruginosa in 2, Stenotrophomonas maltophilia in 2, Staphylococcus aureus in 1, Stenotrophomonas and Staphylococcus aureus in 1, Haemophilus influenza

Table 1. Demographics of study populations.

Gender: F = females, M = males. Age: numbers represent mean (range) age in years. FEV₁: values represent FEV₁ in % of predicted values (24).
doi:10.1371/journal.pone.0046618.t001

|          | N (gender) | Age | FEV₁          |
|----------|------------|-----|---------------|
| Healthy controls | 10 (6F/4M) | 18.9 (14–22) yrs |               |
| CF stable   | 10 (5F/5M) | 13.0 (9–17) yrs | 82.8 (60–102)% |
| CF exacerbation | 20 (10F/10M) | 12.6 (6–17) yrs | 53.1 (36–69)% |

Gender: F = females, M = males. Age: numbers represent mean (range) age in years. FEV₁: values represent FEV₁ in % of predicted values (24).
doi:10.1371/journal.pone.0046618.t001
and Staphylococcus aureus in 1, Inquilinus limbosus in 1). Intravenous antibiotic treatments for exacerbations were given for 14 days and were directed against bacterial pathogens detected in patients’ sputum culture which were Staphylococcus aureus in 12, Haemophilus influenzae in 3, and Pseudomonas aeruginosa in 3 patients.

The ornithine-derived polyamines putrescine, spermidine and spermine could be measured in all sputum samples. Mean (± SEM) concentrations in healthy control samples were 11.91 ± 5.03 µmol/L for putrescine, 0.36 ± 0.07 µmol/L for spermidine and 0.22 ± 0.06 µmol/L for spermine (Table 2). Sputum polyamine concentrations in stable CF patients were similar to healthy controls for putrescine (6.18 ± 1.73 µmol/L) and spermidine (1.62 ± 0.54 µmol/L) but were significantly higher for spermine (1.71 ± 0.60 µmol/L, p = 0.0002) (Figure 2). Spermine concentrations in the two stable CF patients with sterile sputum samples were 0.55 and 0.45 µmol/L, respectively. The spermidine/spermine ratio, which was previously reported to be increased in serum and urine of CF patients [18], was significantly reduced in stable CF sputum compared to healthy controls (1.51 ± 0.26 vs. 3.66 ± 0.53, p<0.01) (Figure 3). In stable CF sputum there was a positive correlation of L-ornithine with both spermidine (R = 0.817, P = 0.01) and spermine (R = 0.838, p = 0.005) but not with putrescine concentrations. There was no correlation of sputum polyamine levels and age.

The concentrations of L-ornithine derived polyamines were highest in CF patients presenting with a pulmonary exacerbation. In comparison to stable CF, patients with pulmonary exacerbation had higher concentrations of putrescine (96.02 ± 38.65 µmol/L, p = 0.005), and spermine (7.32 ± 1.19 µmol/L, p = 0.006). In contrast, mean spermidine concentrations in samples from patients with an exacerbation tended to be lower than in stable CF, although this difference did not reach statistical significance (0.78 ± 0.24 µmol/L, p = 0.075) (Figure 2). The spermidine/spermine ratio was 0.19 ± 0.05 in sputum from patients with an exacerbation, which was significantly lower than in stable CF or healthy controls (<0.0001, respectively) (Figure 3).

Treatment for pulmonary exacerbations resulted in a non-significant decrease in sputum putrescine to 20.59 ± 8.25 µmol/L (p = 0.075), and a significant decrease in spermine to 1.35 ± 0.27 µmol/L (p<0.0001). There was no change in spermidine concentration with antibiotic treatment (0.62 ± 0.19 µmol/L) (Figure 2). The spermidine/spermine ratio significantly increased to 0.61 ± 0.17 (p = 0.0007) (Figure 3). Spermine concentrations after antibiotic treatment were lower than in stable CF (p = 0.0089) and healthy controls (p = 0.033). Spermine concentrations after treatment were not different from stable CF but remained increased compared to healthy controls (p = 0.0017).

| Table 2. L-ornithine derived polyamine concentrations in sputum. |
|---------------------------------------------------------------|
|                  | Putrescine | Spermidine | Spermine | Spd/spm |
| Healthy controls | 11.91±5.03 | 0.88±0.07  | 0.22±0.06 | 3.66±0.53 |
| CF stable        | 6.18±1.73  | 1.62±0.54  | 1.71±0.60 | 1.51±0.26 |
| CF exacerbation  |            |            |          |
| pre              | 96.02±38.65| 0.78±0.24  | 7.32±1.19| 0.19±0.05 |
| post             | 20.59±8.25 | 0.62±0.19  | 1.35±0.27| 0.61±0.17 |

Data shown are mean ± SEM concentrations in µmol/L. For cystic fibrosis (CF) patients with an exacerbation sputum concentrations are shown before (pre) and after (post) antibiotic treatment.

doi:10.1371/journal.pone.0046618.t002

Figure 2. Sputum concentrations of putrescine, spermidine and spermine in healthy controls (HC), stable cystic fibrosis (CF), and CF patients with a pulmonary exacerbation before (pre) and after (post) treatment with intravenous antibiotics (ABx). Each dot represents an individual patient. Numbers indicate p-values for respective group comparison. * = p<0.0001 comparing pre vs. post treatment samples (paired t-test). doi:10.1371/journal.pone.0046618.g002

Despite the increase in spermidine/spermine with treatment, the ratio remains significantly lower compared to both stable CF (p = 0.02) and healthy controls (p = 0.0002) (Table 2) (Figure 3).

As expected, treatment for pulmonary exacerbations resulted in a significant improvement in FEV₁ of 13.4 (~8 to 30)% predicted to an FEV₁ of 66.5 (45–93)% of predicted after treatment. This was associated with a decrease in sputum arginase activity (276.7 ± 39.4 vs. 115.8 ± 33.3 mUnit/mg protein, p = 0.0023) and in the concentration of ornithine, the product of arginase activity (275.5 ± 46.85 vs. 78.01 ± 18.3 µmol/L, p = 0.0005), while NO metabolite levels significantly increased (477.3 ± 93.2 vs. 835.1 ± 127.5 µmol/L, p<0.01). Antibiotic treatment also resulted in a decrease in sputum neutrophil counts (90.2 ± 2.4 vs. 14.6 ± 4.0 x 10⁸/µl, p = 0.001), neutrophil elastase activity (2.59 ± 0.28 vs. 1.29 ± 0.23 U/ml of sputum, p = 0.0005) and IL-8 concentration (178.3 ± 19.9 vs. 87.02 ± 18.2 ng/ml of sputum, p = 0.0026). The changes in either of the L-ornithine derived
polyamine concentration with treatment for pulmonary exacerbations did not correlate with changes in FEV1, sputum NO-metabolites, neutrophil cell counts, neutrophil elastase activity, or IL-8 concentration in sputum. However, changes in sputum NO-metabolites correlated with changes in FEV1 % predicted (R = 0.67, p = 0.004). There was also a significant correlation of the changes in spermine concentration and changes in sputum L-ornithine levels with treatment (spearman R = 0.76, p = 0.0004) (Figure 4).

The effect of spermine on bronchial smooth muscle was evaluated in vitro in bronchial segments obtained from adult mice. Incubation of the bronchi with spermine resulted in a near two-fold increase in acetylcholine-induced force (P<0.01), when compared to the untreated bronchial segments (Figure 5 A). Spermine also significantly reduced the SNP-induced bronchial muscle relaxation (P<0.01). When compared to bronchial segments, a 60% reduction in SNP-induced relaxation was documented in spermine-exposed bronchi at the maximum SNP concentration tested (Figure 5 B).

Discussion

While previous studies looking at imbalances in the L-arginine metabolism in cystic fibrosis have focused on the role of changes in NO production on airway physiology [1–4], the effects of downstream products of increased arginase activity for airways function were largely unknown. We here studied the concentrations of the L-ornithine derived polyamines putrescine, spermidine and spermine in sputum of patients with CF and healthy controls. The main findings of our studies are that (i) in clinically stable CF patients sputum levels of putrescine and spermidine were similar to those found in healthy controls, while concentrations of the higher order polyamine spermine were significantly increased. (ii) In patients presenting with a CF pulmonary exacerbation the sputum levels of spermine were highest and treatment resulted in a
The IC50 of spermine for NOS2 (inducible NOS), an enzyme that active transport, as demonstrated for alveolar epithelial cells [9]. However, tissue concentrations of spermine may be even higher than in sputum as polyamines may accumulate in lung tissue by ornithine to putrescine by ODC can be rate-limiting steps in the polyamine synthesis [26]. However, the expression or activity of ODC in CF airways was not assessed in our study.

The increase in spermine concentrations during treatment correlated significantly with the decrease in sputum L-ornithine, the product of arginine activity. This pattern is consistent with the observed changes in arginase activity with treatment for a CF pulmonary exacerbation in this and previous studies [1–3] and both production of L-ornithine by arginase and conversion of L-ornithine to putrescine by ODC can be rate-limiting steps in the polyamine synthesis [26]. However, the expression or activity of ODC in CF airways was not assessed in our study.

The functional studies in isolated mouse airways demonstrate that the increase in spermine in the airways may contribute to a higher airway resistance by reducing the epithelial-dependent dilatory effect of NO. Also, spermine acts as competitive inhibitor of NOS in various cell types, although it remains unclear whether inhibition of NOS occurs in the lung at physiological polyamines concentrations. The inhibitory effect of spermine on NOS1 (neuronal NOS), the NOS isoform most critical for the regulation of broncho-motor tone [27], was found to have an IC50 value of 56 µM [20]. The measured concentrations of spermine in sputum from CF patients with exacerbation were also in the µmolar range with a mean of 7.3 µM and a max of 18.25 µM; however, tissue concentrations of spermine may be even higher than in sputum as polyamines may accumulate in lung tissue by active transport, as demonstrated for alveolar epithelial cells [9]. The IC50 of spermine for NOS2 (inducible NOS), an enzyme that has been shown to be expressed in CF airway epithelial cells at significantly reduced levels [29], was reported to be higher than for NOS1, i.e. 500 µM (using lysates from endotoxemic rat liver) [30]. Therefore, at the concentrations measured in the CF sputum samples, spermine is more likely to effectively inhibit NOS1 than to have an inhibitory effect on NOS2.

Although there appeared to be no direct correlation of spermine with sputum NO metabolite concentrations or with pulmonary function, changes in sputum NO metabolites during treatment for a CF exacerbation correlated significantly with changes in FEV1 % predicted, which was consistent with previous observations from our group [3]. Relevant to this finding and of possible importance to the mechanism accounting for the spermine effect on NO-mediated airway tone is the observation that spermine can inhibit L-arginine uptake through the cationic amino acid transporter CAT-2, and thereby reducing L-arginine availability for intracellular NOS and NO production, as recently demonstrated in macrophages [31]. Reduced L-arginine availability is thought to contribute to the known NO deficiency and to airway obstruction in CF patients [1–3]. Recent evidence suggests that airway smooth muscle cell contraction may also be controlled by CAT-2 through a spermine-dependent pathway [32].

Interestingly, the experiments with precontracted isolated mouse airways demonstrated that spermine prevented the expected relaxation by the NO-donor SNP. While the underlying mechanism for this effect is unclear, the observation suggests that spermine may indirectly contribute to airway constriction by reducing the availability of NO for bronchodilation. As spermine is known to bind free radicals [33], one possible explanation for our observation is that spermine may also act as NO scavenger. Alternatively, spermine may exert a direct effect on airway constriction as suggested by the increased force generated by airway smooth muscle incubated with spermine; experiments that were conducted in the absence of a NO donor. Contractile effects of spermidine and spermine on airways were previously demonstrated in epithelial-denuded rat tracheal segments [33,34]. In contrast, spermidine and spermine induced transient guinea-pig trachea relaxation [13], while increased Ca2+-activated force generation and shortening velocity was reported in guinea pig ileum in the presence of spermine [35]. Besides effects on airway tone, an increase of polyamines could also have other potential consequences for CF lung disease. For instance, polyamines may exhibit anti-inflammatory characteristics as spermine was shown to protect against lethal sepsis when administered systemically in mice [14]. We did not find any evidence for an anti-inflammatory effect of polyamines in the CF airways, based on the absence of correlations between polyamine concentrations or the changes in spermine during treatment with established sputum markers of airways inflammation (i.e. neutrophil counts, neutrophil elastase activity, or IL-6 levels), or with NO metabolite concentrations.

In summary, we found increased concentrations of the L-ornithine derived polyamine spermine in the airways of patients with CF. Ex-vivo data from the mouse suggested that spermine may influence bronchomotor tone directly and by inhibiting NO-mediated bronchodilation. Further studies are needed to evaluate the potential effects of increased spermine concentrations on other aspects of CF lung disease such as bacterial infection and airway inflammation.

Author Contributions
Conceived and designed the experiments: HG JB FR. Performed the experiments: DS ME ML. Analyzed the data: HG JB. Wrote the paper: HG JB FR.
References

1. Grasemann H, Schwietz R, Matthiesen S, Racke K, Ratjen F (2005) Increased arginine activity in cystic fibrosis airways. Am J Respir Crit Care Med 172: 1523–1528.
2. Grasemann H, Schwietz R, Grasemann G, Vester U, Racke K, et al. (2006) Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respir Res 7: 67.
3. Grasemann H, Al-Saleh S, Scott JA, Shelnaz D, Mehl A, et al. (2011) Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am J Respir Crit Care Med 183: 1363–1368.
4. Grasemann H, Ratjen F (2012) Nitric oxide and L-arginine deficiency in cystic fibrosis. Curr Pharm Des 18: 726–736.
5. Grasemann H, Kurte F, Ratjen F (2006) Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 174: 208–212.
6. Rake K, Warmken M (2010) L-arginine metabolic pathways. The Open Nitric Oxide Journal 3: 9–19.
7. Maarsingh H, Pera T, Meurs H (2008) Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch Pharmacol 378: 171–184.
8. Wu G, Morris SM Jr (1998) Arginine metabolism: nitric oxide and beyond. Biochim J 336 (Pt 1): 1–17.
9. Hoet PH, Nemery B (2000) Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions. Am J Physiol Lung Cell Mol Physiol 278: L417–433.
10. Rabe KF, Dent G, Magnussen H (1995) Hydrogen peroxide contracts human airways in vitro: role of epithelium. Am J Physiol 269: L332–338.
11. Rhoden KJ, Barnes PJ (1989) Effect of hydrogen peroxide on guinea-pig tracheal smooth muscle in vitro: role of cyclo-oxygenase and airway epithelium. Br J Pharmacol 98: 325–330.
12. Dut R, Bazdar EA, Birken E, Sackesen C, Soyer OU, et al. (2008) Oxidative stress and its determinants in the airways of children with asthma. Allergy 63: 1605–1609.
13. Chadwick EW, Fedan JS, Mike P (1985) Polyamines and putreanine relax respiratory tract smooth muscle in the guinea-pig. Eur J Pharmacol 116: 183–190.
14. Zhu S, Ashok M, Li J, Li W, Yang H, et al. (2009) Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Med Mol 15: 273–282.
15. Russell DH, Rosenblum MG, Beckerman RC, Durie BG, Taussig LM, et al. (1976) Altered polyamine metabolism in cystic fibrosis. Pediatr Res 10: 1137–1140.
16. Kneett OM, Frias J, Shulka JB (1976) Polyamine metabolism in cystic fibrosis. Tex Rep Biol Med 34: 187–197.
17. Grasemann H, Shelnaz D, Przecharz P, Ratjen F (2011) The polyamine spermine is increased in cystic fibrosis airway secretions. European Respiratory Journal 38, Suppl. 53: 365A.
18. Al-Saleh S, Dell SI, Grasemann H, Zayu YC, Waters V, et al. (2010) Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr 157: 1006–1011 e1001.
19. Cohen LF, Landgren DW, Farrell PM (1976) Distribution of spermidine and spermine in blood from cystic fibrosis patients and control subjects. Blood 48: 469–475.
20. Byun JA, Lee SH, Jung BH, Choi MH, Moon MH, et al. (2008) Analysis of polyamines as carbamoyl derivatives in urine and serum by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 22: 73–80.
21. Scott JA, North ML, Rafi M, Huang H, Przecharz P, et al. (2011) Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med 184: 779–785.
22. Tessler R, Pan J, Fierer HH, Belik J (2008) Human meconium has a pulmonary vascular and airway smooth muscle relaxant effect. Pediatr Res 64: 24–28.
23. Belik J, Hehne N, Pan J, Behrends S (2007) Soluble guanylate cyclase-dependent relaxation is reduced in the adult rat bronchial smooth muscle. Am J Physiol Lung Cell Mol Physiol 292: L699–703.
24. Casero RA Jr, Pegg AE (1993) Spermidine/spermine N1-acetyltransferase—the turning point in polyamine metabolism. FASEB J 7: 633–661.
25. Wang Y, Devereux W, Woster PM, Casero RA Jr (2001) Cloning and characterization of the mouse polyamine-modulated factor-1 (mPMF-1) gene: an alternatively spliced homologue of the human transcription factor. Biochem J 350: 387–392.
26. Li H, Meininger CJ, Hawker JR Jr, Hayes TE, Kepka-Lehnart D, et al. (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline synthases in endothelial cells. Am J Physiol Endocrinol Metab 280: E75–92.
27. Ward JK, Belvisi MG, Fox AJ, Mira M, Tadjkarimi S, et al. (1993) Modulation of cholinergic neural bronchoconstriction by endogenous nitric oxide and vasoactive intestinal peptide in human airways in vitro. J Clin Invest 92: 736–742.
28. Ho J, Mahnoun ML, el-Fakahany EE (1994) Polyamines inhibit nitric oxide synthase in rat cerebellum. Neurosci Lett 175: 41–45.
29. Kelley TJ, Drumm ML (1998) Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 102: 1200–1207.
30. Blachier F, Mignon A, Soubrane O (1997) Polyamines inhibit L-lysopolyaccharide-induced nitric oxide synthase activity in rat liver cytosol. Nitric Oxide 1: 260–272.
31. Chatuwedil R, Asim M, Hogan S, Lewis ND, Singh K, et al. (2010) Polyamines Impair Immunity to Helicobacter pylori by Inhibiting L-Arginine Uptake Required for Nitric Oxide Production. Gastroenterology 139: 1686–1690, 1698 e1681–1686.
32. Chen H, Macleod G, Deng B, Mason L, Kasaian M, et al. (2007) CAT-2 amplifies the agonist-evoked force of airway smooth muscle by enhancing spermine-mediated phosphothreonyl(dimethyl) sulfate-phosphate-5′-kinase-gamma activity. Am J Physiol Lung Cell Mol Physiol 293: L583–891.
33. Ha HC, Sirisoma NS, Kuppusamy P, Zweier JL, Woster PM, et al. (1996) The natural polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci U S A 93: 11140–11145.
34. Bock JJ, Da Silva A, Mouli M, Landry Y (1992) Natural polyamines stimulate G-proteins. Biochem J 282 (Pt 2): 545–550.
35. Sward K, Pato MD, Nilsson BO, Nordstrom I, Hellbrand P (1995) Polyamines inhibit myosin phosphorylation and increase L-C20 phosphorylation and force in smooth muscle. Am J Physiol 269: C563–C571.